Abstract
Colorectal cancer (CRC) is the third leading cause of cancer-related death in the USA. This high level of CRC death is primarily due to chemoresistance and metastasis. The ability of cancers to maintain tumorigenesis for a long term depends on a subpopulation of cancer cells, the self-renewing cancer-initiating cells (CICs) with cancer stem cell-like properties responsible for tumor initiation, progression, and drug resistance. The CICs can be identified and isolated by CIC-specific cell-surface adhesion marker expression, and CD44v6 is the most frequently functional marker on CICs. Knockout and knockdown of CD44v6 in mice accompanied loss of tumor progression but did not fully regress primary tumor growth indicating that CD44/CD44v6 (Variant 6 of CD44) may have an indispensable role in maintaining CIC turnover. We have recently shown that CRC-CIC enrichment markers and CD44v6 support the maintenance of CICs through communication of the CRC-CIC/niche with the cancer-associated stromal microenvironment. These positive CD44v6 activities for CICs depend on CD44v6’s ability to join tissue microenvironmental cues with growth factor/cytokine signals that transduce signals to membrane receptor proteins or to the nucleus to regulate a variety of transcription factors and their target gene expression levels necessary to maintain the stemness of CICs and to convert differentiated tumor cells into CICs. In this perspective we encapsulate the current findings regarding the potential role of CD44/CD44v6 in the regulation of CICs stemness and the current status of therapies that target CD44v6-positive/CIC mechanisms, which will hold great potential to optimize therapeutic targeting of CRC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CD44v6:
-
variant 6 of CD44
- CICs:
-
cancer-initiating cells
- CRC:
-
colorectal cancer
- CTOS:
-
c-Myc, Twist1, Oct 4, and SOX2
- FR:
-
FOLFOX resistant
- ICD:
-
intracellular domain
- S:
-
sensitive
- Tf:
-
transferrin
- TfR:
-
transferrin receptor
- TM:
-
transmembrane domain
References
Acemel RD, Maeso I, Gomez-Skarmeta JL (2017) Topologically associated domains: a successful scaffold for the evolution of gene regulation in animals. Wiley Interdiscip Rev. Dev Biol 6(3). https://doi.org/10.1002/wdev.265
Adamia S, Maxwell CA, Pilarski LM (2005) Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 5(1):3–14
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7):3983–3988. https://doi.org/10.1073/pnas.0530291100
Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S (2008) Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321(5889):699–702. https://doi.org/10.1126/science.1154884
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61(7):1303–1313
Augestad KM, Rose J, Crawshaw B, Cooper G, Delaney C (2014) Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World J Gastrointest Oncol 6(5):104–111. https://doi.org/10.4251/wjgo.v6.i5.104
Avery S, Inniss K, Moore H (2006) The regulation of self-renewal in human embryonic stem cells. Stem Cells Dev 15(5):729–740. https://doi.org/10.1089/scd.2006.15.729
Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R (2003) Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 17(1):126–140. https://doi.org/10.1101/gad.224503
Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q (2007) Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26(6):836–850
Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65(8):3025–3029. https://doi.org/10.1158/0008-5472.CAN-04-3931
Bartolazzi A, Nocks A, Aruffo A, Spring F, Stamenkovic I (1996) Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J Cell Biol 132(6):1199–1208
Bates RC, Edwards NS, Burns GF, Fisher DE (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 61(13):5275–5283
Bates RC, Elith CA, Thorne RF, Burns GF (1998) Engagement of variant CD44 confers resistance to anti-integrin antibody- mediated apoptosis in a colon carcinoma cell line. Cell Adhes Commun 6(1):21–38
Beck B, Blanpain C (2013) Unravelling cancer stem cell potential. Nat Rev Cancer 13(10):727–738. https://doi.org/10.1038/nrc3597
Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14(6):1122–1132
Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A (1995a) CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128(4):687–698
Bennett KL, Modrell B, Greenfield B, Bartolazzi A, Stamenkovic I, Peach R, Jackson DG, Spring F, Aruffo A (1995b) Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 131(6 Pt 1):1623–1633
Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18(4):251–259
Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K (2012a) Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene
Bourguignon LY, Shiina M, Li JJ (2014) Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv Cancer Res 123:255–275. https://doi.org/10.1016/B978-0-12-800092-2.00010-1
Bourguignon LY, Wong G, Earle C, Chen L (2012b) Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 287(39):32800–32824. https://doi.org/10.1074/jbc.M111.308528
Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC (1997) Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272(44):27913–27918
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749. https://doi.org/10.1038/nrc1694
Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122(20):3461–3472. https://doi.org/10.1182/blood-2013-04-493361
Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113(5):643–655. https://doi.org/10.1016/s0092-8674(03)00392-1
Chen MK, Du Y, Sun L, Hsu JL, Wang YH, Gao Y, Huang J, Hung MC (2019) H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism. J Biol Chem 294(21):8516–8528. https://doi.org/10.1074/jbc.RA118.005953
Cheng C, Yaffe MB, Sharp PA (2006) A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20(13):1715–1720
Cho Y, Lee HW, Kang HG, Kim HY, Kim SJ, Chun KH (2015) Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget 6(11):8709–8721. https://doi.org/10.18632/oncotarget.3325
Choi SH, Takahashi K, Eto H, Yoon SS, Tanabe KK (2000) CD44s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer 85(4):523–526
Cichy J, Pure E (2003) The liberation of CD44. J Cell Biol 161(5):839–843
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17(3):313–319. https://doi.org/10.1038/nm.2304
Colak S, Medema JP (2014) Cancer stem cells--important players in tumor therapy resistance. FEBS J 281 (21):4779-4791. doi:https://doi.org/10.1111/febs.13023
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946–10951
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375(9719):1030–1047. https://doi.org/10.1016/S0140-6736(10)60353-4
De Mattia E, Cecchin E, Toffoli G (2015) Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resist Updat 20:39–70. https://doi.org/10.1016/j.drup.2015.05.003
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3):504–514. https://doi.org/10.1038/sj.cdd.4402283
Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB (1992) A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 116(2):521–531. https://doi.org/10.1083/jcb.116.2.521
Fan CW, Wen L, Qiang ZD, Chen T, Zhou ZG, Mo XM, Hu JK (2012) Prognostic significance of relevant markers of cancer stem cells in colorectal cancer - a meta analysis. Hepatogastroenterology 59(117):1421–1427. https://doi.org/10.5754/hge10727
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65(20):9328–9337. https://doi.org/10.1158/0008-5472.CAN-05-1343
Farabaugh SM, Boone DN, Lee AV (2015) Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) 6:59. https://doi.org/10.3389/fendo.2015.00059
Fehon RG, McClatchey AI, Bretscher A (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11(4):276–287. https://doi.org/10.1038/nrm2866
Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP, Ponta H, Van Putten WL, Herrlich P, Henzen-Logmans SC (1999) Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 84(3):209–215
Foger N, Marhaba R, Zoller M (2001) Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci 114(Pt 6):1169–1178
Gao R, Li D, Xun J, Zhou W, Li J, Wang J, Liu C, Li X, Shen W, Qiao H, Stupack DG, Luo N (2018) CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism. Theranostics 8(22):6248–6262. https://doi.org/10.7150/thno.28721
Ghatak S, Bogatkevich GS, Atnelishvili I, Akter T, Feghali-Bostwick C, Hoffman S, Fresco VM, Fuchs JC, Visconti RP, Markwald RR, Padhye SB, Silver RM, Hascall VC, Misra S (2014) Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-beta1 signaling in interstitial lung disease. J Biol Chem 289(11):7856–7872. https://doi.org/10.1074/jbc.M113.505065
Ghatak S, Hascall VC, Markwald RR, Feghali-Bostwick C, Artlett CM, Gooz M, Bogatkevich GS, Atanelishvili I, Silver RM, Wood J, Thannickal VJ, Misra S (2017b) TGF beta-1 induced CD44v6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. J Biol Chem. https://doi.org/10.1074/jbc.M116.752469
Ghatak S, Hascall VC, Markwald RR, Misra S (2021) FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. Int J Mol Sci. 22(2):753
Ghatak S, Hascall VC, Karamanos N, Markwald RR, Misra S (2022) Interplay between chemotherapy-activated cancer associated fibroblasts and cancer initiating cells expressing CD44v6 promotes colon cancer resistance. Front Oncol 2(12):906415. https://doi.org/10.3389/fonc.2022.906415
Ghatak S, Markwald RR, Hascall VC, Dowling W, Lottes RG, Baatz JE, Beeson G, Beeson CC, Perrella MA, Thannickal VJ, Misra S (2017a) TGF beta-1 regulates CD44v6 expression and activity through ERK-induced EGR1 in pulmonary fibrogenic fibroblasts. J Biol Chem. https://doi.org/10.1074/jbc.M116.752451
Ghatak S, Misra S, Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277(41):38013–38020
Ghatak S, Misra S, Toole BP (2005) Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280(10):8875–8883
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12(2):89–103. https://doi.org/10.1038/nrc3205
Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1(1):27–42. https://doi.org/10.2174/1567201043480036
Goldstein LA, Butcher EC (1990) Identification of mRNA that encodes an alternative form of H-CAM(CD44) in lymphoid and nonlymphoid tissues. Immunogenetics 32(6):389–397
Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC (1989) A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 56(6):1063–1072. https://doi.org/10.1016/0092-8674(89)90639-9
Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481(7381):306–313. https://doi.org/10.1038/nature10762
Greenfield B, Wang WC, Marquardt H, Piepkorn M, Wolff EA, Aruffo A, Bennett KL (1999) Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44. J Biol Chem 274(4):2511–2517
Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13–24
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
He Q, Lesley J, Hyman R, Ishihara K, Kincade PW (1992) Molecular isoforms of murine CD44 and evidence that the membrane proximal domain is not critical for hyaluronate recognition. J Cell Biol 119(6):1711–1719
Heider KH, Kuthan H, Stehle G, Munzert G (2004) CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53(7):567–579. https://doi.org/10.1007/s00262-003-0494-4
Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, Ahorn H, Adolf GR (1996) Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 43(4):245–253
Heldin P, Basu K, Kozlova I, Porsch H (2014) HAS2 and CD44 in breast tumorigenesis. Adv Cancer Res 123:211–229. https://doi.org/10.1016/B978-0-12-800092-2.00008-3
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323. https://doi.org/10.1016/j.stem.2007.06.002
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714–726. https://doi.org/10.1038/nrc3599
Holzel M, Bovier A, Tuting T (2013) Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13(5):365–376. https://doi.org/10.1038/nrc3498
Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69(8):3382–3389
Idzerda RL, Carter WG, Nottenburg C, Wayner EA, Gallatin WM, St John T (1989) Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc Natl Acad Sci U S A 86(12):4659–4663. https://doi.org/10.1073/pnas.86.12.4659
Ilangumaran S, Borisch B, Hoessli DC (1999) Signal transduction via CD44: role of plasma membrane microdomains. Leuk Lymphoma 35(5-6):455–469
Ishida T (2000) Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma. Surg Today 30(1):28–32
Ishii S, Ford R, Thomas P, Nachman A, Steele G Jr, Jessup JM (1993) CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg Oncol 2(4):255–264
Jalkanen S, Jalkanen M (1992) Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 116(3):817–825. https://doi.org/10.1083/jcb.116.3.817
Jamison FW 2nd, Foster TJ, Barker JA, Hills RD Jr, Guvench O (2011) Mechanism of binding site conformational switching in the CD44-hyaluronan protein-carbohydrate binding interaction. J Mol Biol 406(4):631–647. https://doi.org/10.1016/j.jmb.2010.12.040
** L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174. https://doi.org/10.1038/nm1483
Joosten SPJ, Zeilstra J, van Andel H, Mijnals RC, Zaunbrecher J, Duivenvoorden AAM, van de Wetering M, Clevers H, Spaargaren M, Pals ST (2017) MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms. Gastroenterology 153(4):1040–1053. e1044. https://doi.org/10.1053/j.gastro.2017.07.008
Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153(5):893–904
Katoh M (2017) Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol 51(5):1357–1369. https://doi.org/10.3892/ijo.2017.4129
Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121(10):3804–3809. https://doi.org/10.1172/JCI57099
Kozovska Z, Gabrisova V, Kucerova L (2014) Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother 68(8):911–916. https://doi.org/10.1016/j.biopha.2014.10.019
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172–187
Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280(2):638–649
Kurozumi K, Nishida T, Nakao K, Nakahara M, Tsujimoto M (1998) Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer. World J Surg 22 (8):853-857:discussion 857-858
Kursa M, Walker GF, Roessler V, Ogris M, Roedl W, Kircheis R, Wagner E (2003) Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug Chem 14(1):222–231
Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C (2002) Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 277(47):44754–44759. https://doi.org/10.1074/jbc.M206872200
LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62(15):4499–4506
Lau WM, Teng E, Chong HS, Lopez KA, Tay AY, Salto-Tellez M, Shabbir A, So JB, Chan SL (2014) CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res 74(9):2630–2641. https://doi.org/10.1158/0008-5472.CAN-13-2309
Laurent TC, Fraser JR (1992) Hyaluronan. The FASEB Journal 6(7):2397–2404
Lesley J, English N, Charles C, Hyman R (2000a) The role of the CD44 cytoplasmic and transmembrane domains in constitutive and inducible hyaluronan binding. Eur J Immunol 30(1):245–253
Lesley J, Hascall VC, Tammi M, Hyman R (2000b) Hyaluronan binding by cell surface CD44. J Biol Chem 275(35):26967–26975
Lesley J, Hyman R (1992) CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells. Eur J Immunol 22(10):2719–2723
Lesley J, Hyman R (1998) CD44 structure and function. Front Biosci 3:D616–D630
Li HJ, Reinhardt F, Herschman HR, Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2(9):840–855. https://doi.org/10.1158/2159-8290.CD-12-0101
Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR (2012) Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143(3):844–857. https://doi.org/10.1053/j.gastro.2012.06.001
Liu D, Sy MS (1997) Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. J Immunol 159(6):2702–2711
Lokeshwar VB, Fregien N, Bourguignon LY (1994) Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J Cell Biol 126(4):1099–1109. https://doi.org/10.1083/jcb.126.4.1099
Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275–292. https://doi.org/10.1002/path.1706
Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN (2013) Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 210(13):2851–2872. https://doi.org/10.1084/jem.20131195
Lu J, Ye X, Fan F, **a L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, Mani SA, Zweidler-McKay P, Ellis LM (2013) Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23(2):171–185. https://doi.org/10.1016/j.ccr.2012.12.021
Lv L, Liu HG, Dong SY, Yang F, Wang QX, Guo GL, Pan YF, Zhang XH (2016) Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumour Biol 37(7):8811–8824. https://doi.org/10.1007/s13277-015-4755-6
Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U (1994) Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124(1-2):71–82
Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, Smadja-Joffe F, Poupon MF (2009) CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 100(6):918–922. https://doi.org/10.1038/sj.bjc.6604953
Masuda H, Tanaka T, Takahama U (1994) Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 203(2):1175–1180. https://doi.org/10.1006/bbrc.1994.2306
Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, Ko MS, Niwa H (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9(6):625–635. https://doi.org/10.1038/ncb1589
Matzke A, Herrlich P, Ponta H, Orian-Rousseau V (2005) A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res 65(14):6105–6110
Medema JP, Vermeulen L (2011) Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474(7351):318–326. https://doi.org/10.1038/nature10212
Medina M, Dotti CG (2003) RIPped out by presenilin-dependent gamma-secretase. Cell Signal 15(9):829–841. https://doi.org/10.1016/s0898-6568(03)00041-x
Misra S, Ghatak S, Toole BP (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280(21):20310–20315
Misra S, Ghatak S, Zoltan-Jones A, Toole BP (2003) Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278(28):25285–25288
Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S (2008a) Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res 49(3):219–224
Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S (2009) Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem 284(18):12432–12446. https://doi.org/10.1074/jbc.M806772200
Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S (2011) Hyaluronan-CD44 interactions as potential targets for cancer therapy. Febs J 278(9):1429–1443
Misra S, Obeid LM, Hannun YA, Minamisawa S, Berger FG, Markwald RR, Toole BP, Ghatak S (2008b) Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J Biol Chem 283(21):14335–14344
Misra S, Toole BP, Ghatak S (2006) Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 281(46):34936–34941
Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113(5):631–642. https://doi.org/10.1016/s0092-8674(03)00393-3
Mori T, Kitano K, Terawaki S, Maesaki R, Fukami Y, Hakoshima T (2008) Structural basis for CD44 recognition by ERM proteins. J Biol Chem 283(43):29602–29612
Morris SA (2016) Direct lineage reprogramming via pioneer factors; a detour through developmental gene regulatory networks. Development 143(15):2696–2705. https://doi.org/10.1242/dev.138263
Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo T, De Strooper B, Yumoto E, Saya H (2003) Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22(10):1511–1516
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39(6):527–579
Naor D, Sionov RV, Zahalka M, Rochman M, Holzmann B, Ish-Shalom D (1998) Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. Curr Top Microbiol Immunol 231:143–166
Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18(4):260–267
Natarajan TG, Ganesan N, Fitzgerald KT (2010) Cancer stem cells and markers: new model of tumorigenesis with therapeutic implications. Cancer Biomark 9(1-6):65–99. https://doi.org/10.3233/CBM-2011-0173
Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J (1993) The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74(2):257–268. https://doi.org/10.1016/0092-8674(93)90417-o
Neame SJ, Isacke CM (1993) The cytoplasmic tail of CD44 is required for basolateral localization in epithelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts. J Cell Biol 121(6):1299–1310. https://doi.org/10.1083/jcb.121.6.1299
Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, Smith A (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95(3):379–391. https://doi.org/10.1016/s0092-8674(00)81769-9
Niwa H (2007) How is pluripotency determined and maintained? Development 134(4):635–646. https://doi.org/10.1242/dev.02787
Niwa H (2018) The principles that govern transcription factor network functions in stem cells. Development 145(6). https://doi.org/10.1242/dev.157420
Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24(4):372–376. https://doi.org/10.1038/74199
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110
Ochiai S, Nakanishi Y, Mizuno K, Hashimoto S, Inutsuka S, Kawasaki M, Yatsunami J, Hara N (1997) Expression of CD44 standard and CD44 variant 6 in human lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 35(11):1179–1185
Ogino S, Fuchs CS, Giovannucci E (2012) How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 12(6):621–628. https://doi.org/10.1586/erm.12.46
Ogino S, Nishida N, Umemoto R, Suzuki M, Takeda M, Terasawa H, Kitayama J, Matsumoto M, Hayasaka H, Miyasaka M, Shimada I (2010) Two-state conformations in the hyaluronan-binding domain regulate CD44 adhesiveness under flow condition. Structure 18(5):649–656. https://doi.org/10.1016/j.str.2010.02.010
Ohata H, Ishiguro T, Aihara Y, Sato A, Sakai H, Sekine S, Taniguchi H, Akasu T, Fujita S, Nakagama H, Okamoto K (2012) Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res 72(19):5101–5110. https://doi.org/10.1158/0008-5472.CAN-11-3812
Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H (2001) Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 155(5):755–762
Oliferenko S, Kaverina I, Small JV, Huber LA (2000) Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth. J Cell Biol 148(6):1159–1164. https://doi.org/10.1083/jcb.148.6.1159
Oliveira LR, Jeffrey SS, Ribeiro-Silva A (2010) Stem cells in human breast cancer. Histol Histopathol 25(3):371–385. https://doi.org/10.14670/HH-25.371
Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271–1277
Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16(23):3074–3086
Orian-Rousseau V, Sleeman J (2014) CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals. Adv Cancer Res 123:231–254. https://doi.org/10.1016/B978-0-12-800092-2.00009-5
Padua D, Figueira P, Ribeiro I, Almeida R, Mesquita P (2020) The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication. Front Cell Dev Biol 8:442. https://doi.org/10.3389/fcell.2020.00442
Paul CP, Good PD, Winer I, Engelke DR (2002) Effective expression of small interfering RNA in human cells. Nat Biotechnol 20(5):505–508
Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428. https://doi.org/10.1038/nrc2131
Perez-Tomas R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13(16):1859–1876. https://doi.org/10.2174/092986706777585077
Perino M, Veenstra GJ (2016) Chromatin Control of Developmental Dynamics and Plasticity. Dev Cell 38(6):610–620. https://doi.org/10.1016/j.devcel.2016.08.004
Peterson RM, Yu Q, Stamenkovic I, Toole BP (2000) Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol 156(6):2159–2167
Picker LJ, Nakache M, Butcher EC (1989) Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 109(2):927–937. https://doi.org/10.1083/jcb.109.2.927
Pietras A, Katz AM, Ekstrom EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC (2014) Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14(3):357–369. https://doi.org/10.1016/j.stem.2014.01.005
Prasetyanti PR, Medema JP (2017) Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer 16(1):41. https://doi.org/10.1186/s12943-017-0600-4
Prasetyanti PR, Zimberlin CD, Bots M, Vermeulen L, Melo Fde S, Medema JP (2013) Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. Mol Cancer 12(1):126. https://doi.org/10.1186/1476-4598-12-126
Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26(10):2234–2239. https://doi.org/10.1016/j.cellsig.2014.07.011
Prost AC, Menegaux F, Langlois P, Vidal JM, Koulibaly M, Jost JL, Duron JJ, Chigot JP, Vayre P, Aurengo A, Legrand JC, Rosselin G, Gespach C (1998) Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy. Int J Oncol 13(4):871–875
Ramdass B, Duggal R, Minev B, Chowdhary A, Koka P (2013) Functional role of solid tumor stem cells in disease etiology and susceptibility to therapeutic interventions. J Stem Cells 8(3-4):189–231. doi:jsc.2014.8.3/4.189
Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1-2):148–158
Reeder JA, Gotley DC, Walsh MD, Fawcett J, Antalis TM (1998) Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res 58(16):3719–3726
Renouf DJ, Woods R, Speers C, Hay J, Phang PT, Fitzgerald C, Kennecke H (2013) Improvements in 5-year outcomes of stage II/III rectal cancer relative to colon cancer. Am J Clin Oncol 36(6):558–564. https://doi.org/10.1097/COC.0b013e318256f5dc
Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R (2009) Colon cancer stem cells. J Mol Med (Berl) 87(11):1097–1104. https://doi.org/10.1007/s00109-009-0518-4
Rich JN (2016) Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine (Baltimore) 95(1 Suppl 1):S2–S7. https://doi.org/10.1097/MD.0000000000004764
Robinson S, Manas D, Mann D, White S, Mann J (2011) Tumour cytokine production after FOLFOX chemotherapy is mediated by the NF-κB DNA damage response-an important contribution to chemo induced liver injury. EJSO 37(11):P995
Ruiz P, Schwarzler C, Gunthert U (1995) CD44 isoforms during differentiation and development. Bioessays 17(1):17–24
Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19(5):619–625. https://doi.org/10.1038/nm.3175
Safa AR (2016) Resistance to Cell Death and Its Modulation in Cancer Stem Cells. Crit Rev Oncog 21(3-4):203–219. https://doi.org/10.1615/CritRevOncog.2016016976
Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y, Baba H (2013) CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 29(4):1570–1578. https://doi.org/10.3892/or.2013.2273
Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF (2009) Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 96(10):1196–1204. https://doi.org/10.1002/bjs.6683
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27(6):872–877. https://doi.org/10.1200/JCO.2008.19.5362
Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, Hoermann K (2007) Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30(4):927–935
Schmitt M, Metzger M, Gradl D, Davidson G, Orian-Rousseau V (2015) CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ 22(4):677–689. https://doi.org/10.1038/cdd.2014.156
Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van Dongen GA (1993) MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 53(18):4383–4390
Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 89(24):12160–12164
Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S, Zoller M (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177(2):443–455
Shinohara H, Fan D, Ozawa S, Yano S, Van Arsdell M, Viner JL, Beers R, Pastan I, Fidler IJ (2000) Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int J Oncol 17(4):643–651
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, ** DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118(6):2111–2120. https://doi.org/10.1172/JCI34401
Siegel RL, Miller KD (2016) Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A (2017) Jemal A (2017) Colorectal cancer statistics. CA Cancer J Clin 67(3):177–193. https://doi.org/10.3322/caac.21395
Singh AK, Arya RK, Maheshwari S, Singh A, Meena S, Pandey P, Dormond O, Datta D (2015) Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer 136(9):1991–2000. https://doi.org/10.1002/ijc.28804
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828
Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H (1996) Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 135(4):1139–1150
Sneath RJ, Mangham DC (1998) The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51(4):191–200
Sneddon JB, Werb Z (2007) Location, location, location: the cancer stem cell niche. Cell Stem Cell 1(6):607–611. https://doi.org/10.1016/j.stem.2007.11.009
Stamenkovic I, Amiot M, Pesando JM, Seed B (1989) A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56(6):1057–1062
Stamenkovic I, Aruffo A, Amiot M, Seed B (1991) The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10(2):343–348
Su YJ, Lai HM, Chang YW, Chen GY, Lee JL (2011) Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J 30(15):3186–3199. https://doi.org/10.1038/emboj.2011.211
Sugano K, Maeda K, Ohtani H, Nagahara H, Shibutani M, Hirakawa K (2015) Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer. Anticancer Res 35(2):677–682
Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E (2006) Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8(11):1291–1297. https://doi.org/10.1038/ncb1491
Takahashi K, Okita K, Nakagawa M, Yamanaka S (2007) Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2(12):3081–3089. https://doi.org/10.1038/nprot.2007.418
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. https://doi.org/10.1016/j.cell.2006.07.024
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5):1006–1020. https://doi.org/10.1002/stem.30
Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S (1993) T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 361(6407):79–82
Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36(3):446–453. https://doi.org/10.1016/j.ejcts.2009.03.063
Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3(10):e3469. https://doi.org/10.1371/journal.pone.0003469
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G, Papaccio G (2011) Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25(6):2022–2030. https://doi.org/10.1096/fj.10-179036
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G (2013) Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27(1):13–24. https://doi.org/10.1096/fj.12-218222
Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1(4):389–402
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14(3):342–356
Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22(47):7369–7375. https://doi.org/10.1038/sj.onc.1206940
Toyama-Sorimachi N, Miyasaka M (1994) A novel ligand for CD44 is sulfated proteoglycan. Int Immunol 6(4):655–660
Toyama-Sorimachi N, Sorimachi H, Tobita Y, Kitamura F, Yagita H, Suzuki K, Miyasaka M (1995) A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem 270(13):7437–7444. https://doi.org/10.1074/jbc.270.13.7437
Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Heroult M, Augustin HG, Ponta H, Orian-Rousseau V (2009) A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114(25):5236–5244
Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S (1994) ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126(2):391–401. https://doi.org/10.1083/jcb.126.2.391
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wohrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12(11):767–775. https://doi.org/10.1038/nrc3368
Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G (2018) Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 24(34):3834–3848. https://doi.org/10.3748/wjg.v24.i34.3834
Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH (1996) Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 68(4):520–527. https://doi.org/10.1002/(SICI)1097-0215(19961115)68:4<520::AID-IJC19>3.0.CO;2-8
Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5):468–476
Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP (2008a) Cancer stem cells--old concepts, new insights. Cell Death Differ 15(6):947–958
Vermeulen L, Todaro M, de Sousa MF, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP (2008b) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105(36):13427–13432
Vlashi E, Pajonk F (2015) Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol 31:28–35. https://doi.org/10.1016/j.semcancer.2014.07.001
Voog J, Jones DL (2010) Stem cells and the niche: a dynamic duo. Cell Stem Cell 6(2):103–115. https://doi.org/10.1016/j.stem.2010.01.011
Weber GF (2008) Molecular mechanisms of metastasis. Cancer Lett 270(2):181–190. https://doi.org/10.1016/j.canlet.2008.04.030
Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271(5248):509–512. https://doi.org/10.1126/science.271.5248.509
Weg-Remers S, Ponta H, Herrlich P, Konig H (2001) Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J 20(15):4194–4203. https://doi.org/10.1093/emboj/20.15.4194
Wei B, Chen L, Li R, Tian J (2010) Stem cells in gastrointestinal cancers: a matter of choice in cell fate determination. Expert Rev Anticancer Ther 10(10):1621–1633. https://doi.org/10.1586/era.10.52
Weng MS, Chang JH, Hung WY, Yang YC, Chien MH (2018) The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J Exp Clin Cancer Res 37(1):61. https://doi.org/10.1186/s13046-018-0728-0
Williams K, Motiani K, Giridhar PV, Kasper S (2013) CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 238(3):324–338. https://doi.org/10.1177/1535370213480714
Winawer SJ (2005) Screening of colorectal cancer. Surg Oncol Clin N Am 14(4):699–722. https://doi.org/10.1016/j.soc.2005.05.009
Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329(27):1977–1981. https://doi.org/10.1056/NEJM199312303292701
Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG, Wu K (2015) The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther 8:3783–3792. https://doi.org/10.2147/OTT.S95470
Yan Y, Zuo X, Wei D (2015) Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med 4(9):1033–1043. https://doi.org/10.5966/sctm.2015-0048
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917–1920. https://doi.org/10.1126/science.1151526
Yu Q, Toole BP, Stamenkovic I (1997) Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186(12):1985–1996
Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST (2008) Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68(10):3655–3661
Zeilstra J, Joosten SP, van Andel H, Tolg C, Berns A, Snoek M, van de Wetering M, Spaargaren M, Clevers H, Pals ST (2014) Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene 33(5):665–670. https://doi.org/10.1038/onc.2012.611
Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77(3):396–401
Zoller M (2009) Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9(1):40–55. https://doi.org/10.1038/nrc2543
Zoller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11(4):254–267
Acknowledgments
This work was supported by the: (1) 1R03CA167722-01A1 (to SM and SG); (2) 1K12HL141952-02 (to V. C. H.); (3) 2P20GM10399; NIH IDeA Network for SC Biomedical Research Excellence, 40 2 P30 GM131959-01, and (5) 19TPA34900016 to R.R.M
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Ethics declarations
The authors declare that they have no conflicts of interest with the contents of this article.
Author contributions
The perspective was written by Dr. Suniti Misra and Dr. Shibnath Ghatak. Vincent C. Hascall and Dr. Roger R. Markwald reviewed, edited the multiple versions of the drafts, and final versions of the text, figures, and figure legends.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ghatak, S., Hascall, V.C., Markwald, R.R., Misra, S. (2023). CD44: Does CD44v6 Adversely Impact the Prognosis of Cancer Patients?. In: Passi, A. (eds) Hyaluronan. Biology of Extracellular Matrix, vol 14. Springer, Cham. https://doi.org/10.1007/978-3-031-30300-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-031-30300-5_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-30299-2
Online ISBN: 978-3-031-30300-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)